Bevacizumab (Avastin): 2 year

results in choroidal

neovascularization (CNV)

secondary to pathologic myopia

(PM).

regory S. Brinton; Sayed S E H Saif; M. Yasser S. Saif; Ahmed T.S. Saif

No Financial Interest

M. Yasser S. Saif ,MD* Ahmed T.S. Saif, MD**

Gregory S. Brinton, MD***Sayed S E H Saif, MD****

*Assistant Prof of ophthalmology Beni sueif university** lecturer of ophthalmology Fayoum university***Prof of ophthalmology Utah university****Prof of ophthalmology Cairo university

• PURPOSE: To evaluate the safety and efficacy of intravitreal bevacizumab in the treatment of choroidal neovascularization (CNV) secondary to pathologic myopia (PM).

• DESIGN: Prospective, consecutive, nonrandomized, interventional case series.

• PARTICIPANTS: Thirty four eyes of 34 patients with CNV secondary to PM.

• METHODS: Consecutive patients with subfoveal or juxtafoveal CNV secondary to PM were recruited prospectively to receive an intravitreal injection of bevacizumab. Additional injections were performed in eyes with persistent CNV leakage after 2-6 month durations.

• Patients were followed up for 24 months, and BCVA, changes in FFA and OCT results were assessed.

RESULTS: • The mean spherical equivalent

refractive error of the 34 eyes was -10.56+/-3.49 D (range, -6.0D to -19.0D).

• follow-up period : 24 months. • BCVA

– improved in 24 eyes(70.6%) – the same in 6 eyes (17.6%)– decreased in 4(11.8%) eyes.

BCVA

improvedsamedecreased

3 2 1 0 -1 -2 -30

2

4

6

8

10

BCVA lines Gained

Case received 3 injectionsin 2 years

and the CNV is still progressive

2007 Feb 2008

Dec 2008 2009

BCVA improved 3 lines from base line

• The OCT results also showed significant reduction in thickness after treatment.

• No systemic complications were noted after intravitreal injections.

• One eye (2.9%) had an endophthalmitis and resolved on medical treatment. Pre injection 18 month (6

injections

• Thirty eyes (88.2%) received multiple injections (2-6 injections)

• The injection interval varies between 2-13 months

CONCLUSIONS:

• The 24-month outcomes suggest intravitreal bevacizumab to be a promising treatment method for CNV secondary to PM, resulting in both visual and anatomic improvements.